Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma

Tralokinumab is an anti –interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2. The STRATOS 1 biomarker analysis...

Source: BMC Pulmonary Medicine - July 17, 2019 Category: Respiratory Medicine Authors: Mattis Gottlow, David J. Svensson, Ilya Lipkovich, Monika Huhn, Karin Bowen, Peter Wessman and Gene Colice Tags: Technical advance Source Type: research